Results 161 to 170 of about 2,897 (211)

Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals. [PDF]

Curr Pharmacol Rep
Chou P, Shannar A, Pan Y, Dave PD, Xu J, Kong AT.   +5 more
europepmc   +1 more source

Using PBPK to Simulate Target Biopredictive Dissolution Profiles for Long-Acting Injectables - Where to Begin With Critical Bioavailability Attributes? [PDF]

CPT Pharmacometrics Syst Pharmacol
Cleary H, Fotaki N, Persoons T, D'Arcy DM.   +3 more
europepmc   +1 more source

The pH factor: unraveling drug-drug interactions in protein kinase inhibitors through the regulatory lens. [PDF]

Transl Clin Pharmacol
Stankeviciute S, Tsai A, Rayad N, Kruse M.   +3 more
europepmc   +1 more source

Mechanistic Modelling of Lidocaine and Prilocaine Absorption from EMLA Cream upon Topical Application using Physiologically Based Pharmacokinetic Modelling. [PDF]

AAPS PharmSciTech
Telaprolu KC, Tsakalozou E, Ghosh P, Alam K, Grice JE, Roberts MS, Jamei M, Polak S, Clarke JF.   +8 more
europepmc   +1 more source

Developing In Vitro-In Vivo Correlation for Bicalutamide Immediate-Release Dosage Forms with the Biphasic In Vitro Dissolution Test. [PDF]

Pharmaceutics
Ozaksun NT, Incecayir T.
europepmc   +1 more source

Synthesis and Biological Profile of Omaveloxolone: The Cornerstone for Friedreich Ataxia Treatment. [PDF]

Int J Mol Sci
Cordaro M, Neri G, Ansari SAMK, Buccheri R, Scala A, Piperno A.   +5 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling of Efavirenz Nanoparticles: from Animal Model to Human Extrapolation. [PDF]

ACS Omega
da Silva TM, Sarcinelli MA, Cunha Chaves MH, Dias AA, Patricio BFC, Prado LD, Tasso L, Duque MD, Rocha HVA.   +8 more
europepmc   +1 more source

Considering Opportunities and Challenges When Implementing the Model Master File Framework - a Meeting Report. [PDF]

Pharm Res
Tsakalozou E, Fang L, Skoda E, Nicholas T, Kollipara S, Ren K, Grosser S, Rege B, Roy P, Zhu H, Zhao L.   +10 more
europepmc   +1 more source

Development of a Universal In Vivo Predictive Dissolution Method for a Borderline BCS III/IV Drug Guided by Modeling and Simulations─Acyclovir as a Case Study. [PDF]

Mol Pharm
García MA, Tapia F, Escares B, Langguth P.   +3 more
europepmc   +1 more source

Improving In Vitro-In Vivo Correlation (IVIVC) for Lipid-Based Formulations: Overcoming Challenges and Exploring Opportunities. [PDF]

Pharmaceutics
Bourderi-Cambon A, Fadhlaoui K, Garrait G, Lainé E, Dhifallah I, Rossano M, Caisse P, Beyssac E.   +7 more
europepmc   +1 more source